STERIS Gestione
Criteri Gestione verificati 4/4
STERIS Il CEO è Dan Carestio, nominato in Jul2021, e ha un mandato di 5.5 anni. la retribuzione annua totale è $ 11.51M, composta da 9.5% di stipendio e 90.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.065% delle azioni della società, per un valore di $ 14.72M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6 anni e 5.8 anni.
Informazioni chiave
Dan Carestio
Amministratore delegato
US$11.5m
Compenso totale
| Percentuale dello stipendio del CEO | 9.52% |
| Mandato del CEO | 5yrs |
| Proprietà del CEO | 0.07% |
| Durata media del management | 6yrs |
| Durata media del Consiglio di amministrazione | 5.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Seeking Alpha • Jul 27
Steris: A Good Moment To Buy Shares In This Sterilization Leader
Summary Steris provides infection prevention products and sterilization services to medical clientele (such as hospitals, outpatient surgery centers, and pharmaceutical companies). Steris has increased its dividend for 21 consecutive years. The 10-year dividend growth rate of 9.6% is strong, but more recent dividend raises have actually been over 10%. STE has a great financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is over 18. The P/E ratio is now down to 26.6. That’s far lower than its five-year average of 46.8. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jun 24
STE: Share Repurchases And Recurring Platform Earnings Will Support Future Upside
Analysts have made a small adjustment to their price target on STERIS, keeping fair value around $256.86 while fine-tuning assumptions on discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News STERIS reported fiscal 2026 adjusted EPS of $10.17 compared with $9.22 a year earlier and total revenue of $5.94b, with broad-based revenue growth led by healthcare and faster percentage gains in Life Sciences.Aggiornamento narrativa • Jun 04
STE: Share Repurchases And Earnings Outlook Will Support Future Upside
Analysts have trimmed their price target for STERIS to $256.86 from $279.29, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that collectively point to a lower fair value estimate. What's in the News STERIS announced a share repurchase program authorizing the company to buy back up to US$1,000 million of its ordinary shares.Aggiornamento narrativa • May 11
STE: Lower Discount Rate And Stable Assumptions Will Support Future Upside
Analysts have maintained their $279.29 price target for STERIS, supported by a slightly lower discount rate and minor adjustments to long-term revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: Maintained at $279.29 per share, with no change in the updated analysis.Aggiornamento narrativa • Apr 26
STE: Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have reiterated a $279.29 price target for STERIS, citing largely unchanged assumptions on growth, margins, discount rate and future P/E as the basis for maintaining their current valuation framework. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares under an existing buyback program (Key Developments).Aggiornamento narrativa • Apr 11
STE: Completed Buyback And Stable Assumptions Will Support Future Upside
Analysts kept their fair value estimate for STERIS steady at about $279 per share, while slightly updating assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning of their models rather than a shift in the core outlook.Aggiornamento narrativa • Mar 28
STE: Completed Buyback And Refined Assumptions Will Support Future Upside
Analysts have reduced their price target on STERIS by about $2 to reflect slightly updated assumptions for fair value, discount rate, revenue growth, profit margin, and forward P/E, while maintaining the overall thesis. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, accounting for 0.2% of its shares.Articolo di analisi • Mar 24
Is There Now An Opportunity In STERIS plc (NYSE:STE)?
STERIS plc ( NYSE:STE ) received a lot of attention from a substantial price movement on the NYSE over the last few...Aggiornamento narrativa • Mar 11
STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have kept their STERIS price target steady at $281.25, with only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of shares.Aggiornamento narrativa • Feb 25
STE: Completed Share Repurchases And Steady Assumptions Will Support Future Upside
Analysts have slightly trimmed their fair value estimate for STERIS to about $281 from roughly $282, reflecting modest tweaks to assumptions on the discount rate, long term revenue growth, profit margin, and future P/E expectations. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares.Aggiornamento narrativa • Feb 10
STE: Modest Assumption Tweaks Will Support A More Upbeat Fair View
Analysts have slightly adjusted their price target for STERIS to US$281.63, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors suggest a modest recalibration of expectations rather than a major shift in outlook.Aggiornamento narrativa • Jan 27
STE: Share Repurchases And Stable Outlook Will Support A Fair View
Analysts have kept their fair value estimate for STERIS steady at about $281.63 per share, while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the company’s long term earnings power. What's in the News From July 1, 2025 to September 30, 2025, STERIS repurchased 400,000 shares, representing 0.41% of its shares, for $98.64 million under its existing buyback program (Key Developments).Aggiornamento narrativa • Jan 10
STE: Share Repurchases And Steady Guidance Will Support A Fair Outlook
Analysts have kept their fair value estimate for STERIS essentially unchanged at about US$281.63, citing only very small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that do not materially affect their overall price target view. What's in the News STERIS repurchased 400,000 shares from July 1, 2025 to September 30, 2025, representing 0.41% of shares for US$98.64 million, as part of its ongoing buyback program.Articolo di analisi • Jan 09
Here's Why STERIS (NYSE:STE) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Articolo di analisi • Dec 26
Earnings Tell The Story For STERIS plc (NYSE:STE)
With a price-to-earnings (or "P/E") ratio of 36.4x STERIS plc ( NYSE:STE ) may be sending very bearish signals at the...Aggiornamento narrativa • Dec 23
STE: Share Repurchases And Steady Guidance Will Support A Fair Future Outlook
Analysts have modestly raised their price target on STERIS to $281.63, reflecting slightly higher long term growth and profitability expectations, despite largely unchanged model assumptions. What's in the News STERIS completed a share repurchase tranche between July 1 and September 30, 2025, buying back 400,000 shares, or 0.41% of shares outstanding, for $98.64 million (Key Developments).Aggiornamento narrativa • Dec 09
STE: Modest Buybacks And Steady Guidance Will Support A Balanced Outlook
Analysts have modestly raised their price target on STERIS to approximately $282 per share from about $281.60, reflecting slightly lower perceived risk and a steady outlook for revenue growth, profit margins, and long term valuation multiples. What's in the News Completed a share repurchase program totaling 1,307,158 shares, or about 1.32% of shares outstanding, for $298.64 million under the buyback announced on May 3, 2023 (company filing).Aggiornamento narrativa • Nov 25
STE: Stable Outlook And Share Buybacks Will Shape Near-Term Performance
Analysts have raised their price target for STERIS from $278.38 to $281.63. This change reflects modest expectations for improved revenue growth, even though there have been minor adjustments to other key financial metrics.Aggiornamento narrativa • Nov 07
STE: Marginal Profit Margin Gains And Steady Outlook Will Influence Value
Analysts have raised their price target for STERIS from $272.38 to $278.38. They cite marginal improvements in projected profit margins, even though revenue growth expectations have been slightly reduced.Articolo di analisi • Oct 27
Is STERIS (NYSE:STE) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Aggiornamento narrativa • Sep 05
Healthcare Demand And Facility Expansion Will Create Value
With STERIS’s discount rate and future P/E both virtually unchanged, analyst valuation perspectives remain steady, resulting in an unchanged consensus price target of $272.38. What's in the News STERIS completed $200 million in share repurchases, totaling 907,158 shares (0.92%) under its current buyback program; no additional shares were repurchased in the latest quarter.Articolo di analisi • Aug 28
Calculating The Fair Value Of STERIS plc (NYSE:STE)
Key Insights STERIS' estimated fair value is US$227 based on 2 Stage Free Cash Flow to Equity With US$249 share price...Articolo di analisi • Aug 07
STERIS (NYSE:STE) Is Paying Out A Larger Dividend Than Last Year
The board of STERIS plc ( NYSE:STE ) has announced that it will be increasing its dividend by 11% on the 26th of...Seeking Alpha • Mar 22
Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'
Summary Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments. Key risks include weak capital equipment sales due to economic conditions, but overall, Steris's differentiated AST portfolio supports a positive long-term outlook. Read the full article on Seeking AlphaSeeking Alpha • Nov 18
Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
Summary I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with strong performance in the Applied Sterilization Technologies segment. Despite high interest rates, I anticipate a gradual recovery in the biotech industry, driving future double-digit revenue growth in STERIS' AST business. Key risks include potential legal liabilities from EtO emissions and weak near-term growth in healthcare capital equipment revenue. Read the full article on Seeking AlphaSeeking Alpha • Sep 16
Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued
Summary I reiterate a 'Hold' rating for Steris stock with a fair value of $220 per share, citing strong healthcare growth and overvaluation concerns. The divestiture of the dental business and acquisition of Surgical Instrumentation assets will allow Steris to focus on core healthcare and AST businesses. Steris reported 5.4% organic revenue growth and 7% adjusted EPS growth, driven by a 7.2% increase in AST business and strong healthcare performance. Despite strategic moves, cautious outlook on healthcare capital equipment spending due to high-interest rates supports maintaining a 'Hold' rating. Read the full article on Seeking Alpha
Nuova narrativa • Aug 20
Robust Revenue Growth And Expanding Margins In The Medical Equipment Sector
Strong start to the fiscal year and gross margin improvements suggest underappreciated growth momentum and potential for expanding net margins.Seeking Alpha • Aug 13
Steris: Q2 Numbers Solidify Buy Thesis
Summary STE's Q1 FY'25 numbers were in line with expectations, with upsides in the healthcare and AST divisions. The company shows consistent free cash flow production and stable earnings on its capital base. I've revised our estimate on the intrinsic worth of the business to $270 per share, reiterating a buy. Read the full article on Seeking AlphaAnalisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | US$12m | US$1m | US$782m |
| Dec 31 2025 | n/a | n/a | US$709m |
| Sep 30 2025 | n/a | n/a | US$689m |
| Jun 30 2025 | n/a | n/a | US$648m |
| Mar 31 2025 | US$11m | US$1m | US$610m |
| Dec 31 2024 | n/a | n/a | US$617m |
| Sep 30 2024 | n/a | n/a | US$591m |
| Jun 30 2024 | n/a | n/a | US$561m |
| Mar 31 2024 | US$10m | US$1m | US$551m |
| Dec 31 2023 | n/a | n/a | US$1b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$576m |
| Mar 31 2023 | US$8m | US$970k | US$557m |
| Dec 31 2022 | n/a | n/a | -US$28m |
| Sep 30 2022 | n/a | n/a | -US$8m |
| Jun 30 2022 | n/a | n/a | US$377m |
| Mar 31 2022 | US$6m | US$767k | US$285m |
| Dec 31 2021 | n/a | n/a | US$279m |
| Sep 30 2021 | n/a | n/a | US$250m |
| Jun 30 2021 | n/a | n/a | US$286m |
| Mar 31 2021 | US$3m | US$542k | US$397m |
| Dec 31 2020 | n/a | n/a | US$433m |
| Sep 30 2020 | n/a | n/a | US$424m |
| Jun 30 2020 | n/a | n/a | US$413m |
| Mar 31 2020 | US$2m | US$522k | US$408m |
Compensazione vs Mercato: La retribuzione totale di Dan ($USD 11.51M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 14.63M ).
Compensazione vs guadagni: La retribuzione di Dan è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Dan Carestio (53 yo)
5yrs
Mandato
US$11,508,522
Compensazione
Mr. Daniel A. Carestio, also known as Dan, serves as the Chief Executive Officer & President at STERIS plc since July 29, 2021. He had been Senior Vice President and Chief Operating Officer at STERIS plc s...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 5yrs | US$11.51m | 0.065% $ 14.7m | |
| Senior VP | 9.5yrs | US$3.19m | 0.014% $ 3.0m | |
| Senior VP | 13yrs | US$2.95m | 0.036% $ 8.2m | |
| SVP & Chief Human Resources Officer | 6yrs | US$2.07m | 0.014% $ 3.2m | |
| Senior VP & President of Healthcare | 6.9yrs | US$2.45m | 0.018% $ 4.0m | |
| Vice President of Investor Relations & Corporate Communications | no data | Nessun dato | Nessun dato | |
| VP, Chief Compliance & Quality Officer | no data | Nessun dato | 0.0061% $ 1.4m | |
| Senior VP & GM of Life Sciences | 6yrs | Nessun dato | 0.013% $ 2.8m | |
| Senior VP & GM of Dental | 5.1yrs | US$1.92m | Nessun dato | |
| Senior VP & GM of AST | 2.4yrs | Nessun dato | 0.012% $ 2.6m | |
| VP & Corporate Treasurer | 8.9yrs | Nessun dato | 0.0064% $ 1.4m | |
| CEO Emeritus & Senior Advisor | 5yrs | US$1.16m | Nessun dato |
6.0yrs
Durata media
58.5yo
Età media
Gestione esperta: Il team dirigenziale di STE è esperto e expertise (durata media dell'incarico 6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 5.5yrs | US$11.51m | 0.065% $ 14.7m | |
| Independent Director | 18.3yrs | US$355.13k | 0.040% $ 9.0m | |
| Independent Chairman of the Board | 21yrs | US$503.69k | 0.025% $ 5.6m | |
| Independent Director | 21.3yrs | US$349.74k | 0.0096% $ 2.2m | |
| Independent Director | 5.2yrs | US$342.24k | 0% $ 0 | |
| Independent Director | 8.2yrs | US$336.24k | 0.00030% $ 67.6k | |
| Independent Director | 1yr | US$340.78k | Nessun dato | |
| Independent Director | 6yrs | US$354.78k | 0.00060% $ 135.2k | |
| Independent Director | less than a year | US$76.99k | Nessun dato | |
| Independent Director | 3.2yrs | US$343.74k | 0% $ 0 |
5.8yrs
Durata media
66.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di STE sono considerati esperti (durata media dell'incarico 5.8 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/31 09:42 |
| Prezzo dell'azione a fine giornata | 2026/07/31 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
STERIS plc è coperta da 17 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Michael Polark | Baird |
| Erin Wilson Wright | BofA Global Research |
| David Turkaly | Citizens JMP Securities, LLC |